ClinicalTrials.gg
Sign In
Not yet recruitingNCT07830680MiRACleUpdated Sep 24, 2026

Physiopathology of Behavioral Addictions and Biomarkers

An observational study in Food Addiction and Sexual Addiction, sponsored by Nantes University Hospital. Not yet recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Nantes University Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
28
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this observational study is to evaluate the expression of miR-10a-5p in the blood in patients with sexual addiction or food addiction. The main question it aims to answer is : To determine whether adults patients with SA or FA exhibit a distinct blood miR-10a-5p expression profile compared with matched healthy controls.

For all participants, one blood sample will be collected.

02

Conditions studied

  • Food Addiction
  • Sexual Addiction
03

In context

Food Addiction

36 studies on the registry are indexed under Food Addiction; 10 are open to participants now.

This study's planned enrollment of 28 is below the median of 135 across 10 observational studies indexed under Food Addiction.

Browse Food Addiction studies →

Lead sponsor

Nantes University Hospital is the lead sponsor of 839 studies on the registry; 195 are open to participants now.

Browse Nantes University Hospital studies →

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Patients with food or sexual addiction, compared with age- and sex-matched healthy controls with no current addictive disorder.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For patients with FA:

  • Male and females ≥ 18 years old
  • Already in care or newly initiating care
  • Participating to EVALADD cohort
  • Current diagnosis of FA
  • Oral consent provided
  • Affiliated with French social security system or beneficiary from such system

For healthy controls matched to patients with FA:

  • Male and females ≥ 18 years old
  • Oral consent provided
  • Affiliated with French social security system or beneficiary from such system

For patients with SA:

  • Male ≥ 18 years old
  • Already in care or newly initiating care
  • Participating to EVALADD cohort
  • Current diagnosis of SA
  • Oral consent provided
  • Affiliated with French social security system or beneficiary from such system

For healthy controls matched to patients with SA:

  • Male ≥ 18 years old
  • Oral consent provided
  • Affiliated with French social security system or beneficiary from such system

Exclusion criteria

Exclusion Criteria :

For patients with FA:

  • Presence of a current diagnosis of SA
  • Presence of any current addictive disorder (substance [except tobacco] use disorders, gambling disorder, gaming disorder)
  • Presence of any current instable psychiatric disorder (requiring the initiation or adapation of medication)
  • Pregnancy or breastfeeding woman
  • Trusteeship or curatorship
  • Major cognitive impairment
  • Not fluent in French

For patients with SA:

  • Presence of a current diagnosis of FA
  • Presence of any current addictive disorder (substance [except tobacco] use disorders, gambling disorder, gaming disorder)
  • Presence of any current instable psychiatric disorder (requiring the initiation or adapation of medication)
  • Trusteeship or curatorship
  • Major cognitive impairment
  • Not fluent in French

For healthy controls:

  • Without a current diagnosis of FA
  • Without a current diagnosis of SA
  • Presence of any current addictive disorder (substance [except tobacco] use disorders, gambling disorder, gaming disorder)
  • Presence of any current instable psychiatric disorder (requiring the initiation or adapation of medication)
  • Pregnancy or breastfeeding woman
  • Trusteeship or curatorship
  • Major cognitive impairment
  • Not fluent in French
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
28 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Patients with addiction

    Patients with food addiction (FA) or sexual addiction

    Biological: blood sampling

  • Healthy controls

    Healthy controls matched on sex and age to patients with food addiction or sexual addiction

    Biological: blood sampling

Interventions

  • Biologicalblood sampling

    One blood sample wiil be collected into a 10mL K2EDTA BD Vacutainer® tube

06

What researchers measure

Primary outcomes

  1. Blood miR-10a-5p expression

    The concentration of each miR-enriched fraction will be determined by spectrophotometric between patients with SA or FA and matched healthy controls.

    Time frame: 3 months

Secondary outcomes

  1. Blood additional circulating miRs expression

    The concentration of circulating miRs fraction will be determined by spectrophotometric between patients with SA or FA and matched healthy controls.

    Time frame: 3 months

  2. Clinical Characteristics

    Association between blood expression levels of circulating miRs and age

    Time frame: 3 months

  3. Clinical Characteristics

    Association between blood expression levels of circulating miRs and sex

    Time frame: 3 months

  4. Clinical Characteristics

    Association between blood expression levels of circulating miRs and duration of addiction

    Time frame: 3 months

  5. Clinical Characteristics

    Association between blood expression levels of circulating miRs and severity of addiction

    Time frame: 3 months

  6. Clinical Characteristics

    Association between blood expression levels of circulating miRs and tobacco-use

    Time frame: 3 months

  7. Clinical Characteristics

    Association between blood expression levels of circulating miRs and psychiatric disorders

    Time frame: 3 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Oct 2026; primary completion for Mar 2028, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2026
First posted
Sep 21, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Mar 31, 2028
CompletionEst.
Jun 30, 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07830680
Lead sponsor
Nantes University Hospital
Collaborators
INSERM U1216 Grenoble Institut des Neurosciences
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Mar 31, 2028 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

Pr Caroline Victorri-Vigneau
Contact
marie.bronnec@chu-nantes.fr
02.40.84.76.20

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Food Addiction →

Other studies from this sponsor

Nantes University Hospital →

Start the discussion